Cargando…
Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-β1/Smad/miR-192 signaling pathway
Astragaloside IV (ASI) exhibits a wide variety of pharmacological effects in cardiovascular diseases, hepatitis and kidney disease and due to this, ASI has recently become an attractive research target. The present study aimed to determine the effect of ASI on renal fibrosis and the mechanisms under...
Autores principales: | Mao, Qian, Chen, Cuicui, Liang, Huankun, Zhong, Shuhai, Cheng, Xinbo, Li, Laiqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755437/ https://www.ncbi.nlm.nih.gov/pubmed/31572545 http://dx.doi.org/10.3892/etm.2019.7887 |
Ejemplares similares
-
Astragaloside IV Synergizing with Ferulic Acid Ameliorates Pulmonary Fibrosis by TGF-β1/Smad3 Signaling
por: Tong, Jiahuan, et al.
Publicado: (2021) -
Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy
por: Du, Na, et al.
Publicado: (2018) -
Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1/Smad Signaling Pathway
por: Yuan, Xingxing, et al.
Publicado: (2018) -
Astragaloside IV alleviates silica-induced pulmonary fibrosis via inactivation of the TGF-β1/Smad2/3 signaling pathway
por: Li, Nannan, et al.
Publicado: (2021) -
Astragaloside IV alleviates lung inflammation in Klebsiella pneumonia rats by suppressing TGF-β1/Smad pathway
por: Li, Lei, et al.
Publicado: (2023)